Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

TAS-102/Bevacizumab Prolongs OS, PFS in Patients With mCRC and Maintained ECOG PS of 0 or 1

July 5th 2023

Julien Taieb, MD, discusses the importance of combining fluoropyrimidines with bevacizumab, key findings from the SUNLIGHT trial and the post-hoc analysis, and how these results may shake up the colorectal cancer treatment paradigm.

Dr Schrag on Neoadjuvant Chemotherapy and Selective Chemoradiation in Locally Advanced Rectal Cancer

July 5th 2023

Deb Schrag, MD, MPH, discusses findings from the phase 2/3 PROSPECT trial in patients with rectal cancer.

Metastatic Colorectal Cancer: Tumor Sidedness and EGFR-Targeted Therapy

July 5th 2023

Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.

BRAF V600E–Mutant Metastatic Colorectal Cancer: BREAKWATER Study

July 5th 2023

Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.

Treatment Options for BRAF V600E–Mutant Metastatic Colorectal Cancer

June 28th 2023

Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.

Colorectal Cancer: Evolving Role of ctDNA Testing in Practice

June 28th 2023

A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.

Dr Raghav on the Rationale Behind DESTINY-CRC02 in HER2+ mCRC

June 23rd 2023

Kanwal P. S. Raghav, MBBS, MD, discusses the rationale behind the phase 2 DESTINY-CRC02 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with metastatic colorectal cancer (mCRC) with HER2 amplification or overexpression.

ctDNA and MRD Testing in Nonmetastatic Colorectal Cancer

June 21st 2023

A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.

Biomarker Testing in Metastatic Colorectal Cancer

June 21st 2023

Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.

Dr Taieb on Findings from a Post-hoc Analysis of TAS-102 Plus Bevacizumab in Refractory mCRC

June 20th 2023

Julien Taieb, MD, PhD, discusses key findings from a post-hoc analysis of the phase 3 SUNLIGHT trial of combination of trifluridine/tipiracil with bevacizumab in patients with refractory metastatic colorectal cancer.

DESTINY-CRC02 Trial Continues to Support the Use of T-DXd in HER2+ Metastatic CRC

June 19th 2023

Kanwal Pratap Singh Raghav MBBS, MD, discusses data from DESTINY-CRC01 that supported the DESTINY-CRC02 trial, key efficacy and safety data from the trial, and the importance of identifying patients with HER2-positive CRC who may benefit from ADCs like T-DXd in clinical practice.

European Medicines Agency Validates MAA for Fruquintinib in Pretreated mCRC

June 16th 2023

The European Medicines Agency has validated and accepted a marketing authorization application for priority review for fruquintinib for the treatment of adult patients with pretreated metastatic colorectal cancer.

Dr Hitchcock on the Rationale for the ERAsur Trial in Limited mCRC

June 15th 2023

Kathryn Hitchcock, MD, PhD, discusses the rationale for the ongoing phase 3 ERAsur trial investigating total ablative therapy in patients with limited metastatic colorectal cancer and details the methodologies being used in this study.

Franklin on the Effects of Social Determinants of Health on CRC Screening

June 14th 2023

Isabelle Franklin discusses the effects of social determinants of health on rates of colorectal cancer screening.

FDA Greenlights Companion Diagnostic for Encorafenib Plus Cetuximab in BRAF V600E+ mCRC

June 13th 2023

The FDA has approved FoundationOne CDx for use as a companion diagnostic to determine patients with BRAF V600E–mutated metastatic colorectal cancer who may be candidates to receive encorafenib in combination with cetuximab.

Understanding Lynch Syndrome and Associated Cancer Risk: Future Preventive Considerations

June 7th 2023

In this sixth episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, shares future considerations for optimizing the identification of Lynch syndrome and other efforts underway to prevent colorectal cancer in those who have this condition.

Dr Andre on Survival Results From the SOLSTICE Trial in mCRC

June 6th 2023

Thierry Andre, MD, discusses negative overall survival results and updated safety data from the phase 3 SOLSTICE trial in metastatic colorectal cancer.

Fruquintinib/BSC Demonstrates OS/PFS Benefit in Refractory mCRC, Irrespective of Prior Treatment

June 5th 2023

Treatment with fruquintinib plus best supportive care led to improved overall survival and progression-free survival vs placebo plus best supportive care in patients with refractory metastatic colorectal cancer, irrespective of number of prior lines of therapy or type of prior treatment.

Dr Raghav on Trastuzumab Deruxtecan in HER2+ mCRC

June 4th 2023

Kanwal P. S. Raghav, MBBS, MD, discusses primary findings from the phase 2 DESTINY-CRC02 trial (NCT04744831) of fam-trastuzumab deruxtecan-nxki (Enhertu) in patients with metastatic colorectal cancer with HER2 amplification or overexpression.

Trastuzumab Deruxtecan Elicits Promising Antitumor Activity in HER2+ mCRC

June 4th 2023

The 5.4-mg/kg dose of trastuzumab deruxtecan elicited numerically higher activity in patients with HER2-positive, metastatic colorectal cancer compared with the 6.4-mg/kg dose.